• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

结核分枝杆菌和 COVID-19 的双重感染限制了体外对 SARS-CoV-2 的反应能力。

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2.

机构信息

Translational Research Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.

Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.

出版信息

Int J Infect Dis. 2021 Dec;113 Suppl 1:S82-S87. doi: 10.1016/j.ijid.2021.02.090. Epub 2021 Mar 10.

DOI:10.1016/j.ijid.2021.02.090
PMID:33713816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7944764/
Abstract

OBJECTIVES

The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI).

METHODS

We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S).

RESULTS

We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178).

CONCLUSIONS

Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens.

摘要

目的

COVID-19 和结核病（TB）之间的相互作用仍未得到充分描述。在这里，我们使用基于全血的测定平台评估了 COVID-19 患者中结核分枝杆菌（Mtb）和 SARS-CoV-2 的特异性免疫反应，这些患者患有 TB 或潜伏性结核感染（LTBI）。

方法

我们使用 Quantiferon-Plus 格式或源自 SARS-CoV-2 刺突蛋白（Wuhan-Hu-1 分离株）的肽评估来自全血刺激的血浆中 IFN-γ 的水平。

结果

我们连续纳入了 63 名 COVID-19 患者，10 名 TB-COVID-19 患者和 11 名 LTBI-COVID-19 患者。IFN-γ 对 Mtb 抗原的反应与 TB 状态密切相关，因此在 TB-COVID-19 和 LTBI-COVID-19 患者中明显高于 COVID-19 患者（p≤0.0007）。在 35/63 名 COVID-19 患者，7/11 名 LTBI-COVID-19 和仅 2/10 名 TB-COVID-19 患者中发现对 CD4-S 的阳性反应。有趣的是，TB-COVID-19 组中的应答者比 COVID-19 和 LTBI-COVID-19 组中的应答者少（p=0.037 和 0.044，分别）。此外，与 COVID-19 患者（p=0.0336）和 LTBI-COVID-19 患者（p=0.0178）相比，TB-COVID-19 患者对 CD4-S 的 IFN-γ 定量反应最低。

结论

我们的数据表明，COVID-19 患者，无论是患有 TB 还是 LTBI，对 SARS-CoV-2 建立免疫反应的能力都较低，而对 Mtb 特异性抗原的反应能力却保留下来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f20f/7944764/9b37233516f9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f20f/7944764/9b37233516f9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f20f/7944764/9b37233516f9/gr1_lrg.jpg

相似文献

1
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2.结核分枝杆菌和 COVID-19 的双重感染限制了体外对 SARS-CoV-2 的反应能力。
Int J Infect Dis. 2021 Dec;113 Suppl 1:S82-S87. doi: 10.1016/j.ijid.2021.02.090. Epub 2021 Mar 10.
2
[Characteristics of a diagnostic method for tuberculosis infection based on whole blood interferon-gamma assay].基于全血干扰素-γ检测的结核感染诊断方法的特点
Kekkaku. 2006 Nov;81(11):681-6.
3
Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection.结核和 COVID-19 共感染患者免疫损伤的特征。
Int J Infect Dis. 2023 May;130 Suppl 1:S34-S42. doi: 10.1016/j.ijid.2023.03.021. Epub 2023 Mar 21.
4
Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis.比较 T 细胞干扰素 -γ释放试验在活动性和潜伏性结核患者中针对结核分枝杆菌特异性抗原的应用。
Lung. 2010 Aug;188(4):283-7. doi: 10.1007/s00408-010-9238-3. Epub 2010 Apr 27.
5
Impact of antiretroviral and tuberculosis therapies on CD4 and CD8 HIV/M. tuberculosis-specific T-cell in co-infected subjects.抗逆转录病毒和抗结核治疗对合并感染患者 CD4 和 CD8 HIV/M. tuberculosis 特异性 T 细胞的影响。
Immunol Lett. 2018 Jun;198:33-43. doi: 10.1016/j.imlet.2018.04.001. Epub 2018 Apr 7.
6
Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders.在 RD1 反应者中，分枝杆菌 HBHA 甲基化产物可区分活动性和非活动性结核病。
PLoS One. 2011 Mar 29;6(3):e18315. doi: 10.1371/journal.pone.0018315.
7
TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection.结核病和 COVID-19：合并感染的特征和相关并发症探讨。
Front Biosci (Schol Ed). 2022 Mar 1;14(1):6. doi: 10.31083/j.fbs1401006.
8
Role of CD8 T-cell in immune response to tuberculosis-specific antigen in QuantiFERON-TB Gold Plus.CD8 T 细胞在 QuantiFERON-TB Gold Plus 中结核特异性抗原免疫应答中的作用。
J Infect Chemother. 2020 Jun;26(6):570-574. doi: 10.1016/j.jiac.2020.01.011. Epub 2020 Feb 14.
9
New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response.用于检测潜伏性结核感染的新工具：RD1 特异性长期应答的评估。
BMC Infect Dis. 2009 Nov 21;9:182. doi: 10.1186/1471-2334-9-182.
10
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.用于测量 COVID-19 患者体内 SARS-CoV-2 特异性反应的全血检测。
Clin Microbiol Infect. 2021 Feb;27(2):286.e7-286.e13. doi: 10.1016/j.cmi.2020.09.051. Epub 2020 Oct 10.

引用本文的文献

1
Bacterial co-occurrence with pulmonary TB, a respiratory tract infection (RTI): A cross-sectional study in a resource-limited setting.细菌与肺结核（一种呼吸道感染）的共现情况：在资源有限环境下的横断面研究。
J Clin Tuberc Other Mycobact Dis. 2025 May 10;40:100534. doi: 10.1016/j.jctube.2025.100534. eCollection 2025 Aug.
2
Latent tuberculosis coinfection in mild COVID-19 is associated with a distinct immune cell phenotype marked by enhanced cytotoxic degranulation and mitochondrial alterations.轻度新冠肺炎中的潜伏性结核合并感染与一种独特的免疫细胞表型相关，其特征为细胞毒性脱颗粒增强和线粒体改变。
Front Immunol. 2025 May 19;16:1566449. doi: 10.3389/fimmu.2025.1566449. eCollection 2025.
3

本文引用的文献

1
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.体外评估巴瑞替尼的免疫调节作用：对 COVID-19 治疗的启示。
J Infect. 2021 Apr;82(4):58-66. doi: 10.1016/j.jinf.2021.02.023. Epub 2021 Feb 25.
2
Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy.并发空洞性肺结核与 COVID-19 肺炎伴体外免疫细胞无反应性。
Infection. 2021 Oct;49(5):1061-1064. doi: 10.1007/s15010-021-01576-y. Epub 2021 Jan 17.
3
Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patients.
Self-reported COVID-19 severity among persons with tuberculosis infection in western Kenya, 2021.
2021年肯尼亚西部结核病感染者自我报告的新冠病毒病严重程度
PLOS Glob Public Health. 2025 Apr 30;5(4):e0004372. doi: 10.1371/journal.pgph.0004372. eCollection 2025.
4
Clinical outcomes of patients with coronavirus disease 2019 and active tuberculosis co-infection in Beijing China: A retrospective single-center descriptive study.中国北京2019冠状病毒病与活动性肺结核合并感染患者的临床结局：一项回顾性单中心描述性研究
Infect Med (Beijing). 2025 Feb 18;4(1):100169. doi: 10.1016/j.imj.2025.100169. eCollection 2025 Mar.
5
Impact of Severity of COVID-19 in TB Disease Patients: Experience from an Italian Infectious Disease Referral Hospital.2019冠状病毒病（COVID-19）严重程度对结核病患者的影响：来自一家意大利传染病转诊医院的经验
Infect Dis Rep. 2025 Feb 5;17(1):11. doi: 10.3390/idr17010011.
6
Clinical characteristics and variables associated with COVID-19 morbidity and mortality in Luanda, Angola, in the first year of the pandemic.安哥拉罗安达市在大流行第一年与 COVID-19 发病率和死亡率相关的临床特征和变量。
Afr Health Sci. 2023 Dec;23(4):51-63. doi: 10.4314/ahs.v23i4.9.
7
Protective interplay: diminishes SARS-CoV-2 severity through innate immune priming.保护性相互作用：通过先天免疫启动降低 SARS-CoV-2 严重程度。
Front Immunol. 2024 Jun 20;15:1424374. doi: 10.3389/fimmu.2024.1424374. eCollection 2024.
8
Sex disparities of the effect of the COVID-19 pandemic on mortality among patients living with tuberculosis in the United States.美国 COVID-19 大流行对结核病患者死亡率影响的性别差异。
Front Public Health. 2024 Jun 18;12:1413604. doi: 10.3389/fpubh.2024.1413604. eCollection 2024.
9
An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.一种能水解 RNA 的重组迷你抗体可预防甲型流感病毒和冠状病毒在合并感染模型中的感染。
Sci Rep. 2024 Apr 11;14(1):8472. doi: 10.1038/s41598-024-52810-0.
10
Upstaging of Tuberculosis in the Post-COVID-19 Era: A Case Series.新冠疫情后时代结核病的分期上调：病例系列
Cureus. 2024 Feb 22;16(2):e54687. doi: 10.7759/cureus.54687. eCollection 2024 Feb.
新冠康复期后的功能障碍：56例患者的初步发现
Pulmonology. 2021 Sep-Oct;27(5):452-455. doi: 10.1016/j.pulmoe.2020.12.008. Epub 2021 Jan 6.
4
TB and COVID-19 co-infection: rationale and aims of a global study.结核病与新型冠状病毒肺炎合并感染：一项全球研究的基本原理与目标
Int J Tuberc Lung Dis. 2021 Jan 1;25(1):78-80. doi: 10.5588/ijtld.20.0786.
5
COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study.COVID-19 疾病-疾病过程中全血细胞计数参数的时间分析，以及与幸存者和非幸存者患者人口统计学和管理结果的关系：一项纵向描述性队列研究。
PLoS One. 2020 Dec 28;15(12):e0244129. doi: 10.1371/journal.pone.0244129. eCollection 2020.
6
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.免疫疗法，或抗病毒疗法，或两者联合用于治疗 COVID-19：系统评价。
Drugs. 2020 Dec;80(18):1929-1946. doi: 10.1007/s40265-020-01421-w.
7
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients.用于测量 COVID-19 患者体内 SARS-CoV-2 特异性反应的全血检测。
Clin Microbiol Infect. 2021 Feb;27(2):286.e7-286.e13. doi: 10.1016/j.cmi.2020.09.051. Epub 2020 Oct 10.
8
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.急性 COVID-19 患者中针对 SARS-CoV-2 的抗原特异性适应性免疫反应，及其与年龄和疾病严重程度的关联。
Cell. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16.
9
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.2020 年 1 月至 4 月，冠状病毒病大流行对结核病服务的全球影响。
Emerg Infect Dis. 2020 Nov;26(11):2709-2712. doi: 10.3201/eid2611.203163. Epub 2020 Sep 11.
10
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities.意大利 COVID-19 患者的尸检结果：有和无合并症病例的描述性全面尸检研究。
J Infect Dis. 2020 Nov 9;222(11):1807-1815. doi: 10.1093/infdis/jiaa578.